Medical School · Year 2 · Hematology Oncology · includes a quiz and discussion video

Lecture 13: Transfusion Medicine

Unit 2.9: Hematology/Oncology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the ABO and Rh blood group systems
2. Explain compatibility testing and crossmatching
3. Describe blood component therapy indications
4. Explain transfusion reactions and their management
5. Describe special transfusion considerations
6. Explain alternatives to transfusion

Lecture Outline

I. Blood Group Systems

The ABO blood group system is the most clinically significant antigen system in transfusion medicine, defined by the presence or absence of A and B carbohydrate antigens on the red blood cell surface and corresponding naturally occurring antibodies in the plasma. Type A individuals express the A antigen on their red blood cells and carry anti-B antibodies in their plasma. Type B individuals express the B antigen and carry anti-A antibodies. Type AB individuals express both A and B antigens and carry no ABO antibodies, making them universal plasma recipients. Type O individuals express neither A nor B antigen, carrying only the H antigen precursor on their red cells, and possess both anti-A and anti-B antibodies in their plasma, making them universal red cell donors but restricted plasma recipients.

The genetics underlying the ABO system begin with the H gene, which produces the H antigen serving as the precursor substrate for both A and B antigens. The A gene encodes a glycosyltransferase that adds N-acetylgalactosamine to the H antigen, creating the A determinant. The B gene encodes a transferase that adds galactose to the H antigen, producing the B determinant. The O gene is non-functional and produces no transferase, leaving the H antigen unchanged on the red cell surface. The rare Bombay phenotype occurs in individuals with the hh genotype who lack the H gene entirely and therefore cannot produce the H antigen precursor, meaning they cannot express A or B antigens regardless of their ABO genotype, and they develop antibodies against H, A, and B antigens making them compatible only with other Bombay phenotype donors.

The ABO antibodies have distinctive immunologic characteristics that explain the severity of ABO-incompatible transfusion reactions. These antibodies are predominantly of the IgM class and are naturally occurring, developing in early life through environmental exposure to similar carbohydrate antigens found on bacteria and food substances rather than requiring prior transfusion or pregnancy exposure. ABO antibodies are active at 37 degrees Celsius, meaning they are fully functional at body temperature and immediately reactive upon encountering incompatible red cells. They efficiently activate the complement cascade, leading to intravascular hemolysis with rapid destruction of transfused incompatible cells within the circulation. This combination of being naturally present, complement-fixing, and active at body temperature makes ABO antibodies the most clinically significant of all red cell antibodies and explains why ABO-incompatible transfusion produces the most severe acute hemolytic reactions.

The frequency distribution of ABO blood types varies across ethnic populations, which has implications for blood supply management. Among white populations, type O is the most common at approximately 45 percent, followed by type A at 40 percent, type B at 11 percent, and type AB at 4 percent. In Black populations, type O is also the most common at approximately 49 percent, with type A at 27 percent, type B at 20 percent, and type AB at 4 percent. Among Asian populations, the distribution shifts with type O at approximately 40 percent, type A at 28 percent, type B at 27 percent, and type AB at 5 percent. Knowledge of these population frequencies is important for blood bank inventory management and understanding the relative availability of compatible units for patients of different ethnic backgrounds.

<image>Panel A: ABO blood group system diagram showing A, B, AB, and O types with corresponding RBC antigens and plasma antibodies. Panel B: ABO genetics pathway from H antigen precursor through A and B gene modifications with O as non-functional allele. Panel C: Naturally occurring IgM anti-A and anti-B antibodies capable of complement activation and intravascular hemolysis. Panel D: Population frequency distribution of ABO types across different ethnic groups showing O as most common.</image>

II. Rh Blood Group System

The Rh blood group system is the second most important antigen system in transfusion medicine and comprises multiple antigens, of which the D antigen is by far the most immunogenic and clinically significant. The major Rh antigens include D, c, C, e, and E, with the D antigen present in approximately 85 percent of the population who are termed Rh-positive, while the 15 percent lacking the D antigen are Rh-negative. The c, C, e, and E antigens are all common in the population and can stimulate antibody formation following transfusion exposure, though they are substantially less immunogenic than D. Weak D phenotype represents individuals with reduced D antigen expression on their red cells, which may not be detected by standard serologic typing and requires additional testing to identify.

The D antigen holds particular importance because it is the most immunogenic red blood cell antigen after the ABO antigens, meaning that exposure of a D-negative individual to D-positive red cells has a high probability of stimulating antibody formation. Rh-positive individuals carry the D antigen and do not form anti-D antibodies. Rh-negative individuals lack the D antigen, comprising approximately 15 percent of the population, and are at risk of developing anti-D if exposed to D-positive red cells. Weak D individuals express reduced quantities of the D antigen on their red cell surface, a finding that has practical implications for both transfusion and pregnancy management, as policies regarding whether to treat weak D individuals as D-positive or D-negative vary by institution.

Unlike ABO antibodies, anti-D antibodies are not naturally occurring and require prior exposure to the D antigen through either transfusion of D-positive red blood cells or pregnancy with a D-positive fetus for sensitization to occur. Anti-D is an IgG antibody, which has important implications including its ability to cross the placenta and cause hemolytic disease of the fetus and newborn. The primary mechanism of sensitization in obstetric practice occurs when fetal D-positive red cells enter the maternal circulation during delivery, amniocentesis, or other pregnancy complications in a D-negative mother. Prevention of maternal sensitization is achieved through administration of Rh immune globulin (RhoGAM) to D-negative mothers at 28 weeks gestation and within 72 hours of delivery of a D-positive infant, which clears fetal cells from the maternal circulation before the immune system can mount a response.

Hemolytic disease of the newborn represents the most significant clinical consequence of Rh sensitization, occurring when maternal IgG antibodies cross the placenta and attack fetal red blood cells bearing the target antigen. Rh HDN caused by anti-D is the most severe form, as the antibody efficiently destroys D-positive fetal red cells leading to fetal anemia, hydrops fetalis, and kernicterus from severe hyperbilirubinemia. ABO hemolytic disease of the newborn is usually mild because ABO antibodies are predominantly IgM, which does not cross the placenta effectively, and the small amount of IgG anti-A or anti-B that does cross is absorbed by A and B antigens on fetal tissues other than red cells, limiting the severity of hemolysis. Prevention of Rh HDN with RhoGAM has been one of the great successes of modern medicine, virtually eliminating severe Rh hemolytic disease when properly administered to D-negative mothers, as the injected anti-D clears fetal cells before maternal sensitization can occur.

<image>Panel A: Rh blood group system showing D antigen as most immunogenic with 85% D-positive and 15% D-negative population distribution. Panel B: Anti-D formation pathway requiring prior exposure through transfusion or pregnancy with IgG antibody development. Panel C: Hemolytic disease of the newborn pathophysiology with maternal IgG anti-D crossing placenta and attacking fetal D-positive red cells. Panel D: RhoGAM prevention mechanism by clearing fetal cells before maternal sensitization occurs.</image>

III. Compatibility Testing

Pretransfusion testing encompasses a series of laboratory procedures designed to ensure that transfused blood products are compatible with the recipient and will not cause a hemolytic transfusion reaction. ABO typing involves both forward typing, which tests the patient's red blood cells for A and B antigen expression, and reverse typing, which tests the patient's serum for the presence of anti-A and anti-B antibodies, with concordance between forward and reverse typing required to confirm the blood type. Rh typing determines the patient's D antigen status, classifying them as Rh-positive or Rh-negative and guiding selection of appropriately matched red cell units. The antibody screen detects unexpected red cell antibodies beyond the ABO system that could cause hemolytic reactions. The crossmatch represents the final compatibility test performed between the specific donor unit and the recipient's serum before issuing blood for transfusion.

The type and screen procedure forms the foundation of pretransfusion testing and provides the essential information needed to identify compatible blood products. ABO and Rh typing establishes the patient's blood type, determining which red cell units are compatible for transfusion. The antibody screen tests the patient's serum against a panel of standardized screening red cells with known antigen profiles to detect clinically significant unexpected antibodies. If the antibody screen is negative, indicating no unexpected antibodies are present, compatible blood can be made available using an electronic or abbreviated crossmatch. If the antibody screen is positive, indicating the presence of one or more unexpected antibodies, formal antibody identification must be performed using an extended panel of reagent red cells to determine the antibody specificity and select antigen-negative units for transfusion.

Three types of crossmatch procedures exist with progressively increasing sensitivity for detecting incompatibility. The electronic crossmatch uses computer algorithms to verify ABO and Rh compatibility between donor and recipient when the antibody screen is negative, providing rapid and efficient compatibility confirmation without bench-top testing. The immediate spin crossmatch involves mixing recipient serum with donor red cells and centrifuging to detect ABO incompatibility through agglutination, providing a rapid check for the most clinically significant form of mismatch. The full antiglobulin crossmatch is the most sensitive method, involving incubation of recipient serum with donor cells followed by addition of anti-human globulin (Coombs reagent), which detects IgG antibodies coating the donor cells that would not be visible without the antiglobulin enhancement step.

The antibody screen procedure is a critical component of pretransfusion testing that detects unexpected antibodies against red blood cell antigens beyond ABO. The purpose is to identify clinically significant alloantibodies that could cause hemolytic transfusion reactions or hemolytic disease of the newborn. The test uses a standard panel of reagent red cells with known antigen profiles covering the most common and clinically important red cell antigen systems. The indirect antiglobulin test forms the basis of the screening methodology, in which patient serum is incubated with screening cells and then anti-human globulin is added to detect IgG antibodies that have bound to the reagent cell surface. A positive antibody screen necessitates further testing with an extended panel to identify the specific antibody, enabling selection of antigen-negative donor units that will be compatible with the recipient.

<image>Panel A: Type and screen workflow with forward typing testing RBCs for antigens and reverse typing testing serum for antibodies. Panel B: Crossmatch procedure comparing electronic, immediate spin, and full antiglobulin methods with increasing sensitivity. Panel C: Indirect antiglobulin test demonstrating patient serum incubation with reagent cells followed by anti-human globulin addition. Panel D: Antibody screen using standard panel cells with known antigens to detect unexpected clinically significant antibodies.</image>

IV. Blood Components

Packed red blood cells represent the most commonly transfused blood component, prepared by removing most of the plasma from whole blood to create a concentrated red cell product. Each unit has a volume of approximately 300 mL with a hematocrit of 55 to 65 percent, and is stored at 1 to 6 degrees Celsius with additive solutions such as AS-1 or AS-3 (SAGM) that extend shelf life to 42 days. Each unit of packed red blood cells is expected to raise the hemoglobin by approximately 1 g/dL in an average-sized adult. Indications for red cell transfusion center on symptomatic anemia, with a restrictive transfusion threshold of hemoglobin less than 7 g/dL generally recommended for hemodynamically stable patients. A threshold of less than 8 g/dL or the presence of symptoms is used for patients with cardiovascular disease. Acute blood loss situations require transfusion guided by clinical status including hemodynamic parameters and ongoing hemorrhage rather than reliance on a specific hemoglobin value.

Fresh frozen plasma contains all coagulation factors and is prepared by freezing plasma separated from whole blood within 8 hours of collection to preserve factor activity. Each unit has a volume of approximately 250 mL and is stored frozen for up to 1 year, requiring 30 to 45 minutes for thawing before administration. The standard dose is 10 to 15 mL/kg, with the goal of providing sufficient coagulation factor replacement to correct the underlying hemostatic defect. Indications for FFP include multiple coagulation factor deficiency as seen in liver disease and disseminated intravascular coagulation, reversal of warfarin anticoagulation when prothrombin complex concentrate is unavailable, therapeutic plasma exchange for thrombotic thrombocytopenic purpura (TTP), and replacement of specific factor deficiencies when factor concentrates are not available.

Platelet products are available as either single-donor apheresis collections or pooled units derived from 4 to 6 whole blood donations, with one apheresis unit equivalent to approximately 6 pooled units. Platelets are stored at 20 to 24 degrees Celsius with continuous gentle agitation to maintain function, but have a limited shelf life of only 5 days due to the risk of bacterial contamination at room temperature storage. A single apheresis unit or pool is expected to raise the platelet count by 30,000 to 50,000 per microliter in an average adult. Transfusion thresholds vary by clinical context: prophylactic transfusion is indicated when the platelet count falls below 10,000 per microliter in stable patients without active bleeding, below 50,000 per microliter before minor invasive procedures, and below 100,000 per microliter before major surgery or neurosurgical procedures. Active bleeding requires platelet transfusion guided by clinical assessment regardless of a specific threshold.

Cryoprecipitate is a concentrated blood product prepared by thawing fresh frozen plasma at 1 to 6 degrees Celsius and collecting the cold-insoluble precipitate that forms, yielding a small-volume product rich in specific coagulation factors. Each unit contains approximately 15 mL and is enriched in fibrinogen, von Willebrand factor, factor VIII, and factor XIII. The standard dosing is 1 unit per 5 to 10 kilograms of body weight, with the primary indication being fibrinogen replacement when levels fall below 100 to 150 mg/dL, as seen in disseminated intravascular coagulation and massive transfusion protocols where dilutional coagulopathy depletes fibrinogen stores.

<image>Panel A: Packed red blood cell unit showing 300 mL volume, 55-65% hematocrit, storage at 1-6 degrees for 42 days, and expected 1 g/dL hemoglobin rise per unit. Panel B: Fresh frozen plasma preparation from whole blood with all coagulation factors preserved at frozen storage for one year. Panel C: Platelet products comparing single-donor apheresis versus pooled units with room temperature storage and 5-day shelf life. Panel D: Cryoprecipitate composition with fibrinogen, factor VIII, von Willebrand factor, and factor XIII concentrated in 15 mL units.</image>

V. Transfusion Reactions - Acute

Acute hemolytic transfusion reaction is the most feared complication of blood transfusion and is most commonly caused by ABO incompatibility resulting from clerical error, such as mislabeled specimens or administration of the wrong unit to the wrong patient. The mechanism involves complement activation by ABO antibodies binding to incompatible donor red cells, triggering intravascular hemolysis with rapid destruction of transfused cells within the circulation. Symptoms develop within minutes to hours of transfusion initiation and include fever, chills, flank pain from hemoglobin-induced renal vasoconstriction, dyspnea, and hemoglobinuria producing dark or red-colored urine. Complications can be life-threatening and include disseminated intravascular coagulation, acute renal failure from hemoglobin precipitation in the renal tubules, and hemodynamic shock. Management requires immediate cessation of the transfusion, aggressive intravenous fluid administration to maintain renal perfusion and promote hemoglobin clearance, diuretics to support urine output, and close monitoring for the development of DIC.

Febrile non-hemolytic transfusion reaction is the most common type of transfusion reaction, occurring in approximately 1 to 2 percent of transfusions. The cause involves either cytokines that accumulate in stored blood products from residual white blood cells or recipient antibodies directed against donor leukocyte antigens (anti-leukocyte antibodies). The reaction presents with fever defined as a temperature rise of 1 degree Celsius or greater, often accompanied by chills and rigors, typically occurring during or shortly after transfusion. Management requires stopping the transfusion and ruling out a hemolytic reaction, which presents with similar initial symptoms but has far more serious consequences. Prevention is achieved through leukoreduction, which removes white blood cells from blood products during processing and has significantly decreased the incidence of febrile reactions.

Allergic transfusion reactions range from mild urticarial responses to life-threatening anaphylaxis, caused by recipient antibodies reacting against donor plasma proteins. Mild allergic reactions manifest as urticaria (hives) and pruritus (itching) and are common, occurring during or shortly after transfusion. Severe anaphylactic reactions are rare but dangerous, presenting with bronchospasm, hypotension, and cardiovascular collapse. A particularly important cause of anaphylaxis is IgA deficiency, where patients who completely lack IgA develop anti-IgA antibodies that react against IgA in donor plasma, causing severe anaphylactic reactions. Management of mild reactions involves antihistamine administration, while anaphylaxis requires immediate epinephrine, airway management, and hemodynamic support. Patients with IgA deficiency who require transfusion should receive washed cellular products or components from IgA-deficient donors.

Transfusion-related acute lung injury (TRALI) is defined as acute lung injury developing within 6 hours of transfusion in the absence of other risk factors for acute respiratory distress syndrome. The cause typically involves anti-HLA or anti-neutrophil antibodies present in donor plasma, particularly from multiparous female donors, that activate recipient neutrophils in the pulmonary vasculature causing endothelial damage and capillary leak. Clinical presentation includes acute onset of dyspnea, hypoxia requiring supplemental oxygen, and bilateral pulmonary infiltrates on chest radiograph that mimic acute respiratory distress syndrome or pulmonary edema. Management is supportive, with the majority of cases resolving within 48 to 72 hours with appropriate respiratory support, though mechanical ventilation may be required in severe cases. Prevention strategies include preferential use of male or nulliparous female donors for plasma-containing products, which has significantly reduced TRALI incidence.

<image>Panel A: Acute hemolytic transfusion reaction from ABO incompatibility showing fever, chills, flank pain, hemoglobinuria, and DIC with complement-mediated intravascular hemolysis. Panel B: TRALI chest X-ray demonstrating bilateral pulmonary infiltrates within 6 hours of transfusion without cardiac failure. Panel C: Febrile non-hemolytic reaction from cytokine accumulation or anti-leukocyte antibodies with fever and rigors managed by stopping transfusion and ruling out hemolysis. Panel D: Transfusion reaction management algorithm from stopping transfusion through verification of patient identity, blood bank notification, and supportive care.</image>

VI. Transfusion Reactions - Delayed and Other

Delayed hemolytic transfusion reaction occurs 3 to 14 days after transfusion and results from an anamnestic (memory) immune response to a red blood cell antigen to which the patient was previously sensitized but whose antibody titer had declined to undetectable levels at the time of pretransfusion testing. When re-exposed to the antigen through transfusion, the immune system rapidly produces antibody through a secondary response, leading to delayed destruction of the transfused cells. Clinical manifestations include an unexplained fall in hemoglobin, low-grade fever, and jaundice from hemolysis, though symptoms are generally milder than in acute hemolytic reactions. The direct antiglobulin test (DAT, or direct Coombs test) is usually positive, confirming antibody coating of the transfused red cells. Management is primarily supportive, with the critical step being identification and documentation of the offending antibody to ensure that future transfusions use antigen-negative units.

Transfusion-associated circulatory overload (TACO) occurs when the volume of transfused blood products exceeds the patient's cardiovascular capacity to accommodate the fluid load, resulting in pulmonary edema from volume overload. Risk factors include elderly patients, those with underlying cardiac disease, and patients with renal insufficiency who have impaired ability to excrete the extra volume. Symptoms include dyspnea, hypertension, jugular venous distension, and pulmonary edema with bilateral infiltrates on chest radiograph. Elevated B-type natriuretic peptide (BNP) levels help distinguish TACO from TRALI, as BNP rises with volume overload but remains normal in the inflammatory lung injury of TRALI. Prevention involves slow transfusion rates, small-volume aliquots, and administration of diuretics before or between transfusion units in patients at risk.

Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but nearly universally fatal complication caused by engraftment of viable donor T lymphocytes that attack recipient tissues. Risk is highest in immunocompromised patients who cannot reject donor lymphocytes and in situations where the donor is HLA-similar to the recipient, such as transfusions from first-degree relatives. Clinical manifestations develop 1 to 2 weeks after transfusion and include a characteristic skin rash, severe diarrhea, liver dysfunction with elevated transaminases and bilirubin, and profound pancytopenia from bone marrow destruction by donor T cells. The mortality rate exceeds 90 percent, making prevention absolutely essential. Prevention is achieved by irradiation of blood products, which inactivates donor lymphocytes while preserving red cell and platelet function, and is mandated for all transfusions to immunocompromised recipients, intrauterine transfusions, and directed donations from blood relatives.

Infectious complications of transfusion have been dramatically reduced through donor screening questionnaires, serologic testing, and nucleic acid testing (NAT), though a small residual risk remains. The current estimated risk of HIV transmission is approximately 1 in 2 million units transfused. The risk of hepatitis C virus transmission is approximately 1 in 1.5 million units. Hepatitis B virus transmission carries a somewhat higher risk at approximately 1 in 300,000 units due to the window period between infection and detectability. Bacterial contamination represents the most common infectious risk, estimated at approximately 1 in 5,000 units, with platelet products carrying higher risk than red cells because platelets are stored at room temperature, which supports bacterial growth. Prevention relies on comprehensive donor screening, NAT testing to detect viral nucleic acids during the serologic window period, and bacterial detection strategies for platelet products.

<image>Panel A: Delayed hemolytic transfusion reaction timeline occurring 3-14 days post-transfusion from anamnestic antibody response with falling hemoglobin and positive DAT. Panel B: TACO versus TRALI differentiation with hypertension and elevated BNP in volume overload versus hypotension and normal BNP in lung injury. Panel C: TA-GVHD from donor T-cell engraftment causing rash, diarrhea, liver dysfunction, and pancytopenia with greater than 90% mortality prevented by irradiation. Panel D: Infectious risk per unit showing HIV at 1 in 2 million, HCV at 1 in 1.5 million, HBV at 1 in 300,000, and bacterial contamination higher in platelets.</image>

VII. Special Transfusion Situations

Massive transfusion is defined as transfusion of 10 or more units of packed red blood cells within 24 hours or replacement of the patient's entire blood volume, and is most commonly encountered in major trauma, surgical hemorrhage, and obstetric emergencies. Modern massive transfusion protocols employ a balanced 1:1:1 ratio of packed red blood cells to fresh frozen plasma to platelets, an approach derived from military trauma experience demonstrating that early balanced resuscitation with all blood components reduces mortality compared with red cell-heavy strategies. Complications specific to massive transfusion include hypothermia from infusion of cold stored products, hypocalcemia from citrate anticoagulant in blood products binding ionized calcium, and hyperkalemia from potassium leaching out of stored red cells during storage. Monitoring during massive transfusion requires frequent laboratory assessment of coagulation parameters, electrolytes, and ionized calcium, with active rewarming and calcium replacement as needed.

Emergency transfusion situations require the ability to provide blood products before complete compatibility testing can be performed, balancing the risk of transfusion reaction against the immediate threat of hemorrhagic death. When the patient's blood type is unknown, type O packed red blood cells are issued as the universal donor. For women of childbearing age, O Rh-negative units are used to avoid sensitization to the D antigen that could cause hemolytic disease in future pregnancies. For men and post-menopausal women, either O Rh-negative or O Rh-positive units may be used, as the risk of D sensitization is of lesser clinical consequence. When emergency plasma is needed, type AB plasma is used as the universal plasma donor because it contains neither anti-A nor anti-B antibodies. In emergencies, clinicians should not delay transfusion waiting for a full crossmatch, as the immediate clinical need outweighs the small residual risk of transfusion reaction with type-specific or type O uncrossmatched blood.

Special processing of blood products addresses specific clinical needs beyond standard preparation. Leukoreduction, the removal of white blood cells from cellular blood products, prevents febrile non-hemolytic transfusion reactions and reduces the risk of cytomegalovirus transmission, and is now performed routinely for most blood products in many countries. Irradiation of blood products prevents transfusion-associated graft-versus-host disease by inactivating donor lymphocytes and is required for immunocompromised recipients, intrauterine transfusions, and directed donations. Washing of red blood cells or platelets removes plasma proteins and is indicated for patients who have experienced severe allergic or anaphylactic reactions to plasma components, particularly those with IgA deficiency. CMV-negative products or leukoreduced products (considered CMV-safe) are used for immunocompromised patients at high risk for CMV disease.

Neonatal transfusion requires special considerations reflecting the unique physiology and immunologic vulnerability of newborns. Transfusion volumes are carefully calculated as small aliquots of 10 to 15 mL/kg to avoid circulatory overload in the small blood volume of neonates. Irradiation is mandatory for all intrauterine transfusions and is required for neonatal transfusions due to the immature immune system's inability to reject donor lymphocytes. The risk of CMV transmission is particularly high in neonates, especially premature infants, necessitating the use of CMV-safe products. When maternal antibodies are present from conditions such as Rh sensitization or ABO incompatibility, donor blood must be selected to be compatible with both maternal antibodies and the infant's blood type, sometimes requiring antigen-negative units matched to the maternal antibody specificity.

<image>Panel A: Massive transfusion protocol with 1:1:1 ratio of PRBCs, FFP, and platelets addressing coagulopathy, hypothermia, and hypocalcemia. Panel B: Emergency release blood selection with type O red cells for unknown type, Rh-negative for women of childbearing age, and AB plasma as universal donor. Panel C: Special processing methods including leukoreduction for FNHTR and CMV prevention, irradiation for TA-GVHD prevention, and washing for severe allergic reactions. Panel D: Neonatal transfusion considerations with small aliquots, mandatory irradiation, CMV-safe products, and attention to maternal antibodies.</image>

VIII. Transfusion in Specific Diseases

Sickle cell disease presents unique transfusion challenges related to both the underlying hemoglobin disorder and the high transfusion burden these patients experience over their lifetimes. For acute chest syndrome, one of the most serious complications of sickle cell disease, either simple transfusion or exchange transfusion is indicated depending on severity, with exchange transfusion preferred for severe cases to rapidly reduce the proportion of sickle hemoglobin while avoiding the hyperviscosity that can occur with simple transfusion. Chronic transfusion programs targeting maintenance of hemoglobin S below 30 percent are used for primary and secondary stroke prevention, one of the most effective interventions in sickle cell management. Pre-surgical transfusion may be required with a goal hemoglobin of approximately 10 g/dL to reduce perioperative complications. Alloimmunization is a major concern because the frequent transfusion exposure combined with antigen disparities between predominantly Caucasian donor pools and predominantly African-American sickle cell patients leads to high rates of antibody formation, necessitating extended antigen matching beyond ABO and Rh to include C, E, and Kell antigens. Exchange transfusion is preferred over simple transfusion for many acute complications to limit iron loading and more effectively reduce the sickle hemoglobin percentage.

Thalassemia major requires chronic transfusion therapy to maintain hemoglobin between 9 and 10.5 g/dL, suppressing the ineffective erythropoiesis and skeletal deformities that result from untreated disease while allowing normal growth and development. Iron overload is the inevitable consequence of chronic transfusion, with each unit of red cells delivering approximately 200 to 250 mg of iron that the body has no physiologic mechanism to excrete, necessitating lifelong iron chelation therapy. Alloimmunization risk increases with the number of transfusions received, making extended red cell antigen matching an important strategy to reduce antibody formation. These measures collectively improve quality of life and survival but require meticulous long-term management.

Autoimmune hemolytic anemia creates particular challenges for transfusion medicine because the autoantibodies that cause the disease also react with donor red blood cells, making serologic compatibility testing difficult. The direct antiglobulin test (DAT) is typically positive, and the same autoantibody that is destroying the patient's own red cells will also coat and crossmatch-incompatible with donor cells. In these situations, the approach is to select the "least incompatible" unit, meaning the donor unit showing the weakest reactivity with the patient's serum. Transfusion should not be withheld in life-threatening anemia simply because a perfectly compatible unit cannot be found, as the clinical benefit of maintaining oxygen-carrying capacity outweighs the risk of accelerated hemolysis. However, clinicians must recognize that transfused cells will have shortened survival because the autoantibody will also attack donor red cells, requiring close monitoring and potentially more frequent transfusion.

Thrombocytopenic conditions require careful consideration of whether platelet transfusion is appropriate, as the cause of thrombocytopenia determines whether transfusion is helpful, futile, or potentially harmful. In immune thrombocytopenic purpura (ITP), platelet transfusion is usually not effective because the same autoantibodies that destroy the patient's own platelets will rapidly destroy transfused platelets as well, though platelets should be given for life-threatening hemorrhage. In thrombotic thrombocytopenic purpura (TTP), platelet transfusion is contraindicated except when needed for invasive procedures, as exogenous platelets may fuel the ongoing microvascular thrombosis that defines the disease. In heparin-induced thrombocytopenia (HIT), platelet transfusion is similarly contraindicated because it may exacerbate the prothrombotic state. In contrast, thrombocytopenia from bone marrow failure represents a production problem where platelet transfusion is clearly appropriate, as the transfused platelets will have normal survival in the absence of an immune-mediated or consumptive process.

<image>Panel A: Sickle cell disease exchange transfusion for acute chest syndrome reducing HbS below 30% with extended phenotype matching to prevent alloimmunization. Panel B: Chronic transfusion protocol for thalassemia major maintaining hemoglobin 9-10.5 g/dL with iron chelation therapy requirement. Panel C: Autoimmune hemolytic anemia transfusion challenges with positive DAT, least incompatible unit selection, and shortened transfused cell survival. Panel D: Platelet transfusion contraindications in TTP, HIT, and relative avoidance in ITP unless life-threatening bleeding present.</image>

IX. Blood Conservation

Restrictive transfusion strategies have been validated by multiple randomized controlled trials demonstrating that lower hemoglobin thresholds for transfusion are safe and may be superior to liberal strategies in many patient populations. The landmark TRICC trial compared a restrictive threshold of hemoglobin 7 g/dL with a liberal threshold of 10 g/dL in critically ill patients and found similar or better outcomes with the restrictive approach. The FOCUS trial confirmed similar findings in elderly patients with hip fractures and cardiovascular disease, demonstrating that a threshold of 8 g/dL produced outcomes equivalent to a liberal strategy of 10 g/dL. Current recommendations support restrictive transfusion thresholds for hemodynamically stable patients, with each transfusion decision based on symptoms and clinical context rather than a reflexive response to a hemoglobin number. Exceptions where higher thresholds may be appropriate include patients with active bleeding and those experiencing acute cardiac ischemia.

Autologous transfusion techniques allow patients to receive their own blood, eliminating the risks of alloimmunization, transfusion-transmitted infection, and immune-mediated transfusion reactions. Preoperative autologous donation involves collecting the patient's blood in the weeks before scheduled surgery, which is then stored and available for transfusion during or after the procedure. Intraoperative cell salvage, commonly known as "cell saver," collects blood lost during surgery, washes and concentrates the red cells, and returns them to the patient, providing a valuable source of autologous red cells during procedures with significant blood loss. Acute normovolemic hemodilution involves removing blood immediately before surgery while replacing volume with crystalloid or colloid, then returning the collected blood after surgical hemostasis is achieved, so that blood lost during surgery has a lower red cell concentration. These techniques have limitations including time requirements for preoperative donation, cost of cell salvage equipment, and inapplicability in certain clinical scenarios such as contaminated surgical fields.

Pharmacologic alternatives to transfusion provide means to either increase endogenous blood cell production or reduce blood loss, thereby decreasing transfusion requirements. Erythropoietin stimulates red blood cell production from the bone marrow and is used in chronic kidney disease, selected surgical patients, and some patients with anemia of chronic disease. Intravenous iron rapidly corrects iron deficiency, which is a common contributor to preoperative anemia and can be addressed in the weeks before surgery to improve hemoglobin. Tranexamic acid, an antifibrinolytic agent, reduces surgical and traumatic bleeding by stabilizing blood clots and has become a standard component of major trauma resuscitation and many surgical protocols. Desmopressin (DDAVP) enhances platelet function by stimulating release of von Willebrand factor and is useful in uremic platelet dysfunction and mild von Willebrand disease. Vitamin K corrects the coagulopathy produced by warfarin therapy by enabling hepatic synthesis of vitamin K-dependent coagulation factors.

Patient blood management represents a comprehensive, evidence-based approach to optimizing the care of patients who might need transfusion, built on three pillars that collectively reduce transfusion requirements and improve outcomes. The first pillar is optimizing hemoglobin and treating anemia preoperatively, identifying and correcting nutritional deficiencies, chronic disease anemia, and other reversible causes well before scheduled procedures. The second pillar focuses on minimizing blood loss through meticulous surgical technique, use of antifibrinolytic agents such as tranexamic acid, and point-of-care hemostatic monitoring to guide targeted blood component therapy. The third pillar involves harnessing the patient's tolerance of anemia through optimization of oxygen delivery, restrictive transfusion thresholds, and avoidance of unnecessary laboratory blood draws that contribute to iatrogenic blood loss.

<image>Panel A: Restrictive transfusion threshold evidence from TRICC and FOCUS trials supporting hemoglobin 7 g/dL trigger in stable patients with similar outcomes. Panel B: Intraoperative cell salvage with blood collection, washing, and reinfusion of autologous red cells during surgery. Panel C: Pharmacologic alternatives including erythropoietin for RBC production, IV iron for deficiency correction, and tranexamic acid for bleeding reduction. Panel D: Patient blood management pillars showing preoperative anemia optimization, minimizing surgical blood loss, and tolerance of lower hemoglobin thresholds.</image>

X. Regulatory and Safety

Informed consent for blood transfusion is a fundamental legal and ethical requirement that must be obtained before any non-emergency transfusion is administered. The consent process must include discussion of the risks of transfusion including hemolytic reactions, infections, allergic reactions, and volume overload, the benefits of transfusion in the patient's clinical context, and the alternatives to transfusion including watchful waiting, pharmacologic agents, and autologous options. Religious refusal of transfusion, most commonly encountered with Jehovah's Witness patients, must be respected as an exercise of patient autonomy, and clinicians should explore acceptable alternatives while documenting the patient's informed decision. In true medical emergencies where the patient is unable to provide consent and delay would result in death or serious harm, transfusion may proceed without explicit consent under the doctrine of implied consent for emergency treatment.

Patient identification is the single most critical safety step in the transfusion process, as clerical errors resulting in administration of blood to the wrong patient are the leading cause of fatal acute hemolytic transfusion reactions. A physician order is required to initiate the transfusion process. Specimen collection requires positive patient identification at the bedside, with the sample labeled at the time of collection from the correctly identified patient. At the time of transfusion, two patient identifiers must be verified by checking the patient's identification against the compatibility label on the blood unit. The majority of fatal transfusion errors are clerical in nature, resulting from mislabeled samples, incorrect unit selection, or failure to properly verify patient identity at the bedside, rather than from laboratory testing failures.

The management of suspected transfusion reactions follows a standardized protocol designed to minimize harm and facilitate rapid investigation. The first step is to immediately stop the transfusion upon recognition of any signs or symptoms suggesting a reaction. The second step is to maintain intravenous access with normal saline to provide volume support and medication access. The third step is to verify the patient's identity by checking the patient wristband against the blood product label to rule out a wrong-patient transfusion. The fourth step is to notify the blood bank immediately to initiate an investigation. The fifth step is to send blood samples including a post-reaction blood specimen and the remaining blood product to the blood bank for testing including repeat typing, direct antiglobulin test, and visual inspection for hemolysis. The sixth step is to provide appropriate supportive care based on the type and severity of the reaction.

Documentation throughout the transfusion process provides the medical-legal record and enables quality improvement and adverse event tracking. Informed consent must be documented in the medical record before transfusion. Product information including unit number, product type, and expiration date must be recorded for each component transfused. Vital signs must be assessed and documented before transfusion, during transfusion at specified intervals, and after transfusion completion to detect subtle hemodynamic changes that might indicate a developing reaction. The total volume transfused and the duration of each transfusion episode must be recorded. Any transfusion reactions, no matter how minor, must be documented with a description of the signs, symptoms, timing, and management provided.

<image>Panel A: Patient identification protocol with two-identifier verification at sample collection and bedside matching against unit label to prevent clerical errors. Panel B: Transfusion reaction workup steps including stopping transfusion, maintaining IV access, verifying identity, and sending samples to blood bank. Panel C: Post-reaction laboratory evaluation with repeat type and screen, DAT, visual inspection for hemolysis, and hemolysis markers. Panel D: Documentation requirements including consent, product information, vital signs monitoring, transfusion duration, and any adverse reactions.</image>

Summary

• ABO system: Naturally occurring IgM antibodies; most severe reactions
• Rh system: D antigen most immunogenic; IgG anti-D from exposure
• Compatibility: Type and screen, crossmatch; antibody screen critical
• PRBCs: Restrictive threshold (Hgb <7 g/dL in stable patients)
• FFP: Multiple factor deficiency, warfarin reversal, TTP
• Platelets: <10,000 prophylactic; higher thresholds for procedures
• Acute reactions: Hemolytic (ABO), FNHTR, allergic, TRALI
• Delayed reactions: Hemolytic (anamnestic), TACO, TA-GVHD
• Special processing: Leukoreduction, irradiation, washing
• Blood conservation: Restrictive transfusion, cell salvage, pharmacologic alternatives

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown